Emergent BioSolutions | EBS - Sales Revenues


Emergent BioSolutions reported $276.6M in Sales Revenues for its fiscal quarter ending in December of 2023.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
ALKERMES USD 384.5M 9.7M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amarin USD 49.22M 451K Dec/2025
ANI Pharmaceuticals USD 247.06M 19.25M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Exelixis USD 598.66M 860K Dec/2025
Glaxosmithkline GBP 11.46B 59.16M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Ironwood Pharmaceuticals USD 47.71M 74.35M Dec/2025
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 678M 342M Dec/2025
Myriad Genetics USD 209.8M 4.1M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Xoma USD 25K 5M Sep/2024